Novel approaches towards conquering hepatitis B virus infection

World Journal of Gastroenterology

Volumn 13, Issue 6, 2007, Pages 830-836

  Wu, Guo Yi ^a   Chen, Hong Song ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Antiviral drugs; Drug evaluation; Gene therapy; Hepatatis B virus; Immunomodulatory agents

Indexed keywords

2 AMINO 9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)PURINE BIS(PIVALOYLOXYMETHYL) ESTER; ADEFOVIR DIPIVOXIL; ALAMIFOVIR; ALPHA INTERFERON; AMDOXOVIR; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; BAY 41 4109; CLEVUDINE; DENDRITIC CELL VACCINE; ELVUCITABINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; IMMUNOMODULATING AGENT; INTERLEUKIN 12; INTERLEUKIN 18; LAMIVUDINE; MESSENGER RNA; MIV 210; NUCLEOSIDE ANALOG; PLACEBO; PYRIMIDINE NUCLEOSIDE DERIVATIVE; REMOFOVIR; TELBIVUDINE; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALTORCITABINE;

ANTIBIOTIC RESISTANCE; CELL TRANSFER; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; GENE THERAPY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOTHERAPY; INHIBITION KINETICS; LIFE CYCLE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; REVIEW; RNA TRANSCRIPTION; SEROCONVERSION; UNSPECIFIED SIDE EFFECT; VIRUS CAPSID; VIRUS MUTATION; VIRUS REPLICATION; WOODCHUCK;

EID: 33947530311     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v13.i6.830     Document Type: Review

References (70)

1. World Health Organization warns of growing "crisis of suffering." 1997. http://www.who.ch/whr/1997/presse.htm
2. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-323
3. Lok AS, Lai CL, Wu PC, Leung EK. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988; 2: 298-302
4. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982; 29: 403-415
5. Hoofnagle JH, Lau D. New therapies for chronic hepatitis B. J Viral Hepat 1997; 4 Suppl 1: 41-50
6. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 332: 2682-2695
7. Akuta N, Suzuki F, Kobayashi M, Matsuda M, Sato J, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment. Intervirology 2005; 48: 174-182
8. Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001; 120: 1828-1853
9. Liaw YF, Leung N, Guan R, Lau GK, Merican I, McCaughan G, Gane E, Kao JH, Omata M. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005; 25: 472489
10. Lok AS. The maze of treatments for hepatitis B. N Engl J Med 2005; 352: 2743-2746
11. Lai CJ, Terrault NA. Antiviral therapy in patients with chronic hepatitis B and cirrhosis. Gastroenterol Clin North Am 2004; 33: 629-654, x-xi
12. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, Schmid P, Condreay LD, Gauthier J, Kuhns MC, Liang TJ, Hoofnagle JH. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32: 828-834
13. Locarnini S, Hatzakis A, Heathcote J, Keeff EB, Liang TJ, Mutimer D, Pawlotsky JM, Zoulim F. Management of antiviral resistance in patients with chronic hepatitis B. Antivir Ther 2004; 9: 679-693
14. Doo E, Liang TJ. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology 2001; 120: 1000-1008
15. Lim SG, Ng TM, Kung N, Krastev Z, Volfova M, Husa P, Lee SS, Chan S, Shiffman ML, Washington MK, Rigney A, Anderson J, Mondou E, Snow A, Sorbel J, Guan R, Rousseau F. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 2006; 166: 49-56
16. van Bommel F, Zollner B, Sarrazin C, Spengler U, Huppe D, Moller B, Feucht HH, Wiedenmann B, Berg T. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44: 318-325
17. Levy V, Grant RM. Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls. Clin Infect Dis 2006; 43: 904-910
18. Lee HS, Chung YH, Lee K, Byun KS, Paik SW, Han JY, Yoo K, Yoo HW, Lee JH, Yoo BC. A 12-week clevudine therapy showed potent and durable antiviral activity in hbeag-positive chronic hepatitis B. Hepatology 2006; 43: 982-988
19. Peek SF, Cote PJ, Jacob JR, Toshkov IA, Hornbuckle WE, Baldwin BH, Wells FV, Chu CK, Gerin JL, Tennant BC, Korba BE. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax). Hepatology 2001; 33: 254-266
20. Chong Y, Chu CK. Understanding the unique mechanism of L-FMAU (clevudine) against hepatitis B virus: molecular dynamics studies. Bioorg Med Chem Lett 2002; 12: 3459-3462
21. Kim JW, Park SH, Louie SG. Telbivudine: a novel nucleoside analog for chronic hepatitis B. Ann Pharmacother 2006; 40: 472-478
22. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, Lloyd D, Brown NA. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528-536
23. Tenney DJ, Levine SM, Rose RE, Walsh AW, Weinheimer SP, Discotto L, Plym M, Pokornowski K, Yu CF, Angus P, Ayres A, Bartholomeusz A, Sievert W, Thompson G, Warner N, Locarnini S, Colonno RJ. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother 2004; 48: 3498-3507
24. Fung SK, Lok AS. Management of hepatitis B patients with antiviral resistance. Antivir Ther 2004; 9: 1013-1026
25. Kock J, Schlicht HJ. Analysis of the earliest steps of hepadnavirus replication: genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity. J Virol 1993; 67: 4867-4874
26. Deres K, Schroder CH, Paessens A, Goldmann S, Hacker HJ, Weber O, Kramer T, Niewohner U, Pleiss U, Stoltefuss J, Graef E, Koletzki D, Masantschek RN, Reimann A, Jaeger R, Gross R, Beckermann B, Schlemmer KH, Haebich D, Rubsamen-Waigmann H. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 2003; 299: 893-896
27. Stray SJ, Bourne CR, Punna S, Lewis WG, Finn MG, Zlotnick A. A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly. Proc Natl Acad Sci USA 2005; 102: 8138-8143
28. Weber O, Schlemmer KH, Hartmann E, Hagelschuer I, Paessens A, Graef E, Deres K, Goldmann S, Niewoehner U, Stoltefuss J, Haebich D, Ruebsamen-Waigmann H, Wohlfeil S. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res 2002; 54: 69-78
29. King RW, Ladner SK, Miller TJ, Zaifert K, Perni RB, Conway SC, Otto MJ. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)beta-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1998; 42: 3179-3186
30. Delaney WE 4th, Edwards R, Colledge D, Shaw T, Furman P, Painter G, Locarnini S. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother 2002; 46: 3057-3060
31. Cheng YC, Ying CX, Leung CH, Li Y. New targets and inhibitors of HBV replication to combat drug resistance. J Clin Virol 2005; 34 Suppl 1: S147-S150
32. Block TM, Lu X, Mehta AS, Blumberg BS, Tennant B, Ebling M, Korba B, Lansky DM, Jacob GS, Dwek RA. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med 1998; 4: 610-614
33. Dyson MR, Murray K. Selection of peptide inhibitors of interactions involved in complex protein assemblies: association of the core and surface antigens of hepatitis B virus. Proc Natl Acad Sci USA 1995; 92: 2194-2198
34. Bottcher B, Tsuji N, Takahashi H, Dyson MR, Zhao S, Crowther RA, Murray K. Peptides that block hepatitis B virus assembly: analysis by cryomicroscopy, mutagenesis and transfection. EMBO J 1998; 17: 6839-6845
35. Sprengers D, Janssen HL. Immunomodulatory therapy for chronic hepatitis B virus infection. Fundam Clin Pharmacol 2005; 19: 17-26
36. Turelli P, Mangeat B, Jost S, Vianin S, Trono D. Inhibition of hepatitis B virus replication by APOBEC3G. Science 2004; 303: 1829
37. Rosler C, Kock J, Kann M, Malim MH, Blum HE, Baumert TF, von Weizsacker F. APOBEC-mediated interference with hepadnavirus production. Hepatology 2005; 42: 301-309
38. Lei YC, Hao YH, Zhang ZM, Tian YJ, Wang BJ, Yang Y, Zhao XP, Lu MJ, Gong FL, Yang DL. Inhibition of hepatitis B virus replication by APOBEC3G in vitro and in vivo. World J Gastroenterol 2006; 12: 4492-4497
39. Koziel MJ. The immunopathogenesis of HBV infection. Antivir Ther 1998; 3: 13-24
40. Beckebaum S, Cicinnati VR, Gerken G. DNA-based immunotherapy: potential for treatment of chronic viral hepatitis? Rev Med Virol 2002; 12: 297-319
41. Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C, Michel ML. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 2004; 40: 874-882
42. Liu SA, Xu DZ, Zhang JP, Huang KL, Yao J, Xu LF, Yuan ZH, Wen YM. [Immune response for phase I clinical trial of a hepatitis B immunogenic complex therapeutic vaccine, YIC. Zhonghua Ganzangbing Zazhi 2006; 14: 89-92
43. Wu YZ, Zhao JP, Wan Y, Jia ZC, Zhou W, Bian J, Ni B, Zou LY, Tang Y. Mimovirus: a novel form of vaccine that induces hepatitis B virus-specific cytotoxic T-lymphocyte responses in vivo. J Virol 2002; 76: 10264-10269
44. Akbar SM, Horiike N, Onji M, Hino O. Dendritic cells and chronic hepatitis virus carriers. Intervirology 2001; 44: 199-208
45. Zheng BJ, Zhou J, Qu D, Siu KL, Lam TW, Lo HY, Lee SS, Wen YM. Selective functional deficit in dendritic cell - T cell interaction is a crucial mechanism in chronic hepatitis B virus infection. J Viral Hepat 2004; 11: 217-224
46. Akbar SM, Furukawa S, Hasebe A, Horiike N, Michitaka K, Onji M. Production and efficacy of a dendritic cell-based therapeutic vaccine for murine chronic hepatitis B virus carrierer. Int J Mol Med 2004; 14: 295-299
47. Moynagh PN. TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway. Trends Immunol 2005; 26: 469-476
48. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511
49. Tosi MF. Innate immune responses to infection. J Allergy Clin Immunol 2005; 116: 241-249; quiz 250
50. Isogawa M, Robek MD, Furuichi Y, Chisari FV. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 2005; 79: 7269-7272
51. BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines - yesterday, today, and tomorrow. Lancet Infect Dis 2002; 2: 425-431
52. Livingston BD, Crimi C, Grey H, Ishioka G, Chisari FV, Fikes J, Grey H, Chesnut RW, Sette A. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection. J Immunol 1997; 159: 1383-1392
53. Heathcote J, McHutchison J, Lee S, Tong M, Benner K, Minuk G, Wright T, Fikes J, Livingston B, Sette A, Chestnut R. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group. Hepatology 1999; 30: 531-536
54. Stevceva L. Cytokines and their antagonists as therapeutic agents. Curr Med Chem 2002; 9: 2201-2207
55. Robek MD, Wieland SF, Chisari FV. Inhibition of hepatitis B virus replication by interferon requires proteasome activity. J Virol 2002; 76: 3570-3574
56. Wieland SF, Guidotti LG, Chisari FV. Intrahepatic induction of alpha/ beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice. J Virol 2000; 74: 4165-4173
57. Kakimi K, Lane TE, Chisari FV, Guidotti LG. Cutting edge: Inhibition of hepatitis B virus replication by activated NK T cells does not require inflammatory cell recruitment to the liver. J Immunol 2001; 167: 6701-6705
58. Carreno V, Moreno A, Galiana F, Bartolome FJ. Alpha- and gamma-interferon versus alpha-interferon alone in chronic hepatitis B. A randomized controlled study. J Hepatol 1993; 17: 321-325
59. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005; 79: 3851-3854
60. Stevceva L. Cytokines and their antagonists as therapeutic agents. Curr Med Chem 2002; 9: 2201-2207
61. Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Sereti I, Sachau W, Kelly G, Metcalf JA, Davey RT Jr, Falloon J, Polis MA, Tavel J, Stevens R, Lambert L, Hosack DA, Bosche M, Issaq HJ, Fox SD, Leitman S, Baseler MW, Masur H, Di Mascio M, Dimitrov DS, Lane HC. Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest 2005; 115: 2139-2148
62. Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, Slos P, Squiban P. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci USA 2004; 101 Suppl 2: 14567-14571
63. Cavanaugh VJ, Guidotti LG, Chisari FV. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol 1997; 71: 3236-3243
64. Carreno V, Zeuzem S, Hopf U, Marcellin P, Cooksley WG, Fevery J, Diago M, Reddy R, Peters M, Rittweger K, Rakhit A, Pardo M. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. J Hepatol 2000; 32: 317-324
65. Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J Virol 2002; 76: 10702-10707
66. Sun J, Gao Y, Chen HS, Wang SX, Li RB, Jiang D, Wei L, Wang Y. Transfusion of multi-factors activated immune cells as a novel treatment for patients with chronic hepatitis B. J Clin Virol 2006; 35: 26-32
67. Wu J, Nandamuri KM. Inhibition of hepatitis viral replication by siRNA. Expert Opin Biol Ther 2004; 4: 1649-1659
68. Konishi M, Wu CH, Wu GY. Delivery of hepatitis B virus therapeutic agents using asialoglycoprotein receptor-based liver-specific targeting. Methods Mol Med 2004; 96: 163-173
69. Ryther RC, Flynt AS, Phillips JA 3rd, Patton JG. siRNA therapeutics: big potential from small RNAs. Gene Ther 2005; 12: 5-11
70. Sullenger BA, Gilboa E. Emerging clinical applications of RNA. Nature 2002; 418: 252-258